Implantation techniques (predilatation, sizing, and post-dilatation) and the incidence of scaffold thrombosis and revascularisation in lesions treated with an everolimus-eluting bioresorbable vascular scaffold: insights from the AIDA trial
EuroIntervention 2018;14:e434-e442 published online April 2018 published online e-edition July 2018. DOI: 10.4244/EIJ-D-17-01152
Ruben Y.G. Tijssen1, MD; Robin P. Kraak1, MD; Joelle Elias1, MD; Ivo M. van Dongen1, MD; Deborah N. Kalkman1, MD; Martina Nassif1, MD; Yohei Sotomi1, MD; Taku Asano1, MD; Yuki Katagiri1, MD; Carlos Collet1, MD; Jan J. Piek1, MD, PhD; Jose P. Henriques1, MD, PhD; Robbert J. de Winter1, MD, PhD; Jan G.P. Tijssen1, PhD; Yoshinobu Onuma2,3, MD, PhD; Patrick W. Serruys4, MD, PhD; Joanna J. Wykrzykowska1*, MD, PhD
1. AMC Heartcenter, Academic Medical Center - University of Amsterdam, Amsterdam, the Netherlands; 2. Cardialysis BV, Rotterdam, the Netherlands; 3. Erasmus MC, Rotterdam, the Netherlands; 4. Imperial College London, London, United Kingdom
Aims: Specific implantation strategies have been proposed for the Absorb bioresorbable vascular scaffold (Absorb BVS) to optimise outcomes. We aimed to analyse whether the occurrence of d